

LISTING OF THE CLAIMS

1-55. **(Canceled).**

56. **(Previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of an ACE inhibitor and of an OP/BMP morphogen, formulated with a pharmaceutically acceptable salt, carrier, excipient or diluent.

57-68. **(Canceled)**

69. **(Previously Presented)** The pharmaceutical composition of claim 56, wherein the ACE inhibitor is Enalapril.

70. **(Previously Presented)** The pharmaceutical composition of claim 56, wherein the morphogen is the polypeptide of SEQ ID NO: 3.

71. **(Previously Presented)** The pharmaceutical composition of claim 56, wherein the morphogen is a first polypeptide including at least a C-terminal cysteine domain of a protein selected from: a pro form, a mature form, or a soluble form of a second polypeptide, wherein said second polypeptide is: OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, or BMP9.

72. **(Previously Presented)** The pharmaceutical composition of claim 56, wherein said morphogen comprises a polypeptide having at least 70% homology or 50% identity with an amino acid sequence of a C-terminal seven-cysteine domain of human OP-1 (SEQ ID NO: 2).

73. **(Previously Presented)** The pharmaceutical composition of claim 72, wherein said polypeptide has at least 75% homology or 60% identity with an amino acid sequence of a C-terminal seven-cysteine domain of human OP-1 (SEQ ID NO: 2).
74. **(Previously Presented)** The pharmaceutical composition of claim 72, wherein said polypeptide has at least 80% homology or 70% identity with an amino acid sequence of a C-terminal seven-cysteine domain of human OP-1 (SEQ ID NO: 2).
75. **(Previously Presented)** The pharmaceutical composition of claim 72, wherein said polypeptide has at least 90% identity with an amino acid sequence of a C-terminal seven-cysteine domain of human OP-1 (SEQ ID NO: 2).
76. **(Previously Presented)** The pharmaceutical composition of claim 56, wherein said ACEI is: any one compound of the formulas I-XXVIII or their salts thereof; acylmercapto and mercaptoalkanoyl prolines; captopril (1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline); ether or thioether mercaptoacyl prolines; zofenopril; carboxyalkyl dipeptides; enalapril (N-(1-ethoxycarbonyl-3-phenylpropyl)-L-ananyl-L-proline); lisinopril; quinapril; ramipril; carboxyalkyl dipeptide mimics; cilazapril; benazapril; phosphinylalkanoyl prolines; fosinopril;trandolopril; phosphonamidate substituted amino or imino acids; phosphonate substituted amino or imino acids and salts thereof; ceronapril ((S)-1-[6-amino-2-[[hydroxyl(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline); BRL 36,378; MC-838; CGS 14824 (3-([1-ethoxycarbonyl-3-phenyl-(1S)-propyl]-amino)-2,3,4,5-tetrahydro-2-oxo-1-(3S)-benzazepine-1 acetic acid HCL); CGS 16,617 (3(S)-[[[(1S)-5-amino-1-carboxypentyl]amino]2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid); Cetapril

(alacepril, Dainippon); Ru 44570; Cilazapril; Ro 31-2201; Lisinopril; Indalapril (delapril); Rentiapril (fentiapril, Santen); Indolapril; Spirapril; Perindopril; Quinapril; CI 925 ([3S-[2[R(*)R(*)]]3R(*)]-2-[2-[[1-(ethoxy-carbonyl)-3-phenylpropyl]amino[-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid HCL); WY-44221; mercapto-containing compounds; pivopril; YS980; Omapatrilat; Alacepril; moveltopril; quinaprilat; moexipril; perinodpril (S-9490); pentopril; ancovenin; phenacein; or nicotianamin.

77. **(Canceled)**

78. **(Previously presented)** A packaged pharmaceutical comprising the pharmaceutical composition of claim 56, in association with instructions for administering the composition to a mammal for treatment or prevention of chronic renal failure.